EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate

Lena Huber iD, Constanze Kohler, Anne Lammert iD, Claudia Scherl iD, Sonja Ludwig iD, Annette Affolter iD, Nicole Rotter iD, Frederic Jungbauer iD

Cancer Reports · 2025

DOI: 10.1002/cnr2.70369 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Lena Huber und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery, University Medical Center Mannheim, Heidelberg University, Germany. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors, Head and Neck Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Head and neck squamous cell carcinoma (HNSCC) is a globally significant disease with poor survival outcomes. Immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab have improved treatment paradigms, yet their real‐world efficacy and the factors influencing treatment outcomes remain underexplored.

Aims

This study aimed to evaluate real‐world outcomes of pembrolizumab and nivolumab therapy in patients with HNSCC and to identify clinical and laboratory factors associated with overall survival (OS), progression‐free survival (PFS), and objective response rate (ORR). Methods and Results We conducted a retrospective analysis of 45 HNSCC patients treated with pembrolizumab or nivolumab at the University Medical Center Mannheim. Patient‐specific factors, including tumor characteristics, PD‐L1 expression, and laboratory parameters, were assessed using Kaplan–Meier estimation, log‐rank tests, and multivariate regression models. The median OS and PFS were 10.4 months and 7.4 months, respectively, with an ORR of 22%. A tumor proportion score (TPS) ≥ 50% and absence of smoking or alcohol abuse significantly improved ORR, while female sex, high neutrophil‐to‐lymphocyte ratio (NLR), and elevated leukocyte counts were associated with inferior OS and PFS. Real‐world outcomes largely aligned with the pivotal trials Keynote‐048 and CheckMate 141.

Conclusion

This study underscores the predictive value of TPS and patient lifestyle factors in ICI treatment for HNSCC. The findings also highlight sex‐specific differences, as well as NLR and leukocyte count as potential prognostic factors. Larger, more diverse cohorts are needed to confirm these results and refine patient selection strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Squamous Cell Carcinoma of Head and NeckImmune Checkpoint InhibitorsHead and Neck NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAntibodies, Monoclonal, HumanizedNivolumabAdultAged, 80 and overProgression-Free SurvivalB7-H1 AntigenPrognosisSurvival Rate

Stichwörter der Autor:innen

head and neck squamous cell carcinomaimmune checkpoint inhibitorsimmunotherapy responsenivolumabpembrolizumabpredictive biomarkersprogression‐free survivalreal‐world outcomessurvival analysis

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedpembrolizumabNivolumabB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Otolaryngology, Head and Neck Surgery, University Medical Center Mannheim, Heidelberg University, Germany.
  • Medical Faculty, Mainz University, Germany.

ORCID-Profile: Lena Huber, Anne Lammert, Claudia Scherl, Sonja Ludwig, Annette Affolter, Nicole Rotter, Frederic Jungbauer

Zitieren

APA

Huber, L., Kohler, C., Lammert, A., Scherl, C., Ludwig, S., Affolter, A., Rotter, N., & Jungbauer, F. (2025). Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate. Cancer Reports. https://doi.org/10.1002/cnr2.70369

Vancouver

Huber L, Kohler C, Lammert A, Scherl C, Ludwig S, Affolter A, et al. Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate. Cancer Reports. 2025. doi:10.1002/cnr2.70369

BibTeX
@article{Huber2025,
  author = {Huber, Lena and Kohler, Constanze and Lammert, Anne and Scherl, Claudia and Ludwig, Sonja and Affolter, Annette and Rotter, Nicole and Jungbauer, Frederic},
  title = {Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70369}
}
Kostenlos starten →